Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia.

Hsiao CJ, Tzai TS, Chen CH, Yang WH, Chen CH.

Dis Markers. 2016;2016:8915809. doi: 10.1155/2016/8915809.

2.

High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients.

Wei W, Leng J, Shao H, Wang W.

Int J Clin Exp Med. 2015 Sep 15;8(9):16606-12.

3.
4.
5.

Doctors' approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study.

Pickles K, Carter SM, Rychetnik L.

BMJ Open. 2015 Mar 17;5(3):e006367. doi: 10.1136/bmjopen-2014-006367.

6.

A dual-reporter, diagnostic vector for prostate cancer detection and tumor imaging.

Richter JR, Mahoney M, Warram JM, Samuel S, Zinn KR.

Gene Ther. 2014 Oct;21(10):897-902. doi: 10.1038/gt.2014.68.

7.

What do the screening trials really tell us and where do we go from here?

Etzioni RD, Thompson IM.

Urol Clin North Am. 2014 May;41(2):223-8. doi: 10.1016/j.ucl.2014.01.002. Review.

8.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

9.

Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?

Hudson MA, Luo S, Chrusciel T, Yan Y, Grubb RL 3rd, Carson K, Scherrer JF.

Urol Oncol. 2014 Jan;32(1):34.e9-18. doi: 10.1016/j.urolonc.2013.01.003.

10.

Data to support PSA screening for younger men lacking.

Miller AB, Harvey BJ.

CMAJ. 2013 Mar 5;185(4):325. doi: 10.1503/cmaj.113-2106. No abstract available.

11.

A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.

Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD.

Adv Anat Pathol. 2013 Jan;20(1):39-44. doi: 10.1097/PAP.0b013e31827b665b. Review.

12.

The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.

Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB.

Cancer. 2012 Dec 1;118(23):5955-63. doi: 10.1002/cncr.27594.

13.

Historical prostate cancer screening and treatment outcomes from a single institution.

Cross DS, Ritter M, Reding DJ.

Clin Med Res. 2012 Aug;10(3):97-105. doi: 10.3121/cmr.2011.1042.

14.

The impact of PLCO control arm contamination on perceived PSA screening efficacy.

Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R.

Cancer Causes Control. 2012 Jun;23(6):827-35. doi: 10.1007/s10552-012-9951-8.

15.

Biopsy follow-up of prostate-specific antigen tests.

Zeliadt SB, Buist DS, Reid RJ, Grossman DC, Ma J, Etzioni R.

Am J Prev Med. 2012 Jan;42(1):37-43. doi: 10.1016/j.amepre.2011.08.024.

16.

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM.

Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.

17.

What we have learned from randomized trials of prostate cancer screening.

Hoffman RM, Smith AY.

Asian J Androl. 2011 May;13(3):369-73. doi: 10.1038/aja.2010.181.

18.

What happens after an elevated PSA test: the experience of 13,591 veterans.

Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW.

J Gen Intern Med. 2010 Nov;25(11):1205-10. doi: 10.1007/s11606-010-1468-9.

19.

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H.

Lancet Oncol. 2010 Aug;11(8):725-32. doi: 10.1016/S1470-2045(10)70146-7.

20.

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Hocking WG, Hu P, Oken MM, Winslow SD, Kvale PA, Prorok PC, Ragard LR, Commins J, Lynch DA, Andriole GL, Buys SS, Fouad MN, Fuhrman CR, Isaacs C, Yokochi LA, Riley TL, Pinsky PF, Gohagan JK, Berg CD; PLCO Project Team..

J Natl Cancer Inst. 2010 May 19;102(10):722-31. doi: 10.1093/jnci/djq126.

Items per page

Supplemental Content

Support Center